• Hummelstown, PA (May 05, 2015) – Oncoceutics, Inc. announced publication of a research article in the journal Molecular Cancer, which describes the discovery of ONC201 as a selective lead compound with a novel chemical structure and novel mechanism of action that warranted clinical testing.In an attempt to identify inducers of tumor cell death that spare normal cells and overcome therapeutic resistance, a small molecule library that represents 140,000 compounds was screened to identify compounds that fulfill certain molecular criteria to enable this profile. Using a series of in vitro and in vivo assays, ONC201 was the only compound to show significant apoptosis in tumor cells without harming normal cells by employing pathways that are highly conserved within the immune-oncology armamentarium. The uniqueness of its biological activity is similarly mirrored in its molecular structure, which possesses a pharmacophore that is unique among 63 million publicly indexed molecules. This study cumulatively indicates that ONC201 is a selectively active antitumor agent that possesses a novel mechanism of action that includes, but extends well beyond, the induction of the TRAIL gene and highlights the therapeutic potential of this novel class of anticancer drugs.

    “Even during the discovery process, it was immediately apparent that ONC201 has a clearly differentiated mechanism that translates to an uncommonly favorable safety and efficacy profile relative to many cancer drugs that are on the market,” said Joshua Allen, PhD, VP-Research & Development of Oncoceutics .”That said, the extraordinarily simplistic administration of ONC201, ie oral at infrequent dosing intervals, added another level of unexpectedness to our discovery that made it an ideal drug candidate”, he added.

    “The majority of conventional cancer therapies and even more modern targeted therapies have significant toxicities that can limit their use in patients. This article describes the discovery process that identified ONC201 as a mutation-agnostic and non-toxic anti-cancer agent that represents a versatile therapeutic option in a range of unmet medical need indications, eg when other therapies are no longer effective or too toxic and burdensome to be administered” commented Wafik El-Deiry, MD, PhD, FACP, Professor of Oncology, Co-Program Leader of Molecular Therapeutics, Deputy Cancer Center Director for Translational Research at Fox Chase Cancer Center, Scientific Founder of Oncoceutics.

    The link to the journal article is available here.

    About Oncoceutics

    Oncoceutics, Inc. is a drug discovery and development company targeting the most potent suppressor pathways in human cancer. The first lead compound to result from this program is ONC201, a small molecule drug with a unique mechanism of action that causes significant anti­‐tumor activity in a variety of types of human cancer. The Company is currently enrolling patients in clinical trials of ONC201, which began in January 2015, following acceptance by the U.S. Food and Drug Administration of the Company’s Investigational New Drug (IND) application for ONC201 in 2014. Oncoceutics and collaborative groups have received approximately $5 million in grants over the last two years from the National Institutes of Health, the Pennsylvania Department of Health, and The Musella Foundation, and the company has leveraged additional funding from academic medical research partners that support multiple Phase I/II Clinical trials.

    Visit Oncoceutics or contact Rohinton Tarapore for more information.

    Safe Harbor  Forward‐Looking Statements

    To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company’s development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward‐looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward‐looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

Photostream